Bijal D. Shah, MD, on CAR T-cell therapy and mantle cell lymphoma
Bijal D. Shah, MD, discusses the progress made regarding CAR T-cell therapy and mantle cell lymphoma.
Related Articles
Dato-DXd Misses OS End Point in TROPION-Breast01 Trial of HR+ Breast Cancer
Datopotamab deruxtecan previously showed statistically significant improvement in progression-free survival in patients with HR+, HER2-low, or HER2-negative breast cancer.
Adjuvant cCRT Improves Disease Control, But Increases AEs in Breast Cancer
Concurrent chemoradiation yielded similar contralateral breast recurrence outcomes vs a sequential approach in early-stage breast cancer.
Biosignature Test May Predict Residual Risk Post-BCS/RT in HER2+ DCIS
Use of DCISionRT may open new options for tailored treatments among patients with HER2-positive ductal carcinoma in situ.
Neoadjuvant/Adjuvant Nivolumab/Chemo Approved by FDA in Resectable NSCLC
Findings from the phase 3 CheckMate 77T trial support the approval of nivolumab plus chemotherapy for resectable NSCLC.
Retrospective Radiotherapy in IBD Data May Warrant Prospective Research
Retrospective study data show that patients with inflammatory bowel disease may not require modification of standard radiotherapy for pelvic malignancies.
Support Groups May Help Manage Talquetamab-Related AEs in Multiple Myeloma
Samantha Shenoy, NP, MSN, suggests that support groups may help comfort patients experiencing adverse effects negatively impacting quality of life.
Starting at the Front Line in Metastatic Pancreatic Cancer As New Options Emerge, How Do You Select and Sequence?
Experts in gastrointestinal cancer focus on frontline therapy options for patients with pancreatic cancer.
Talquetamab/Daratumumab Shows Durable Responses in R/R Multiple Myeloma
The combination of talquetamab plus daratumumab yields improved patient outcomes in those with relapsed/refractory multiple myeloma.
Talquetamab Combo Yields Enduring Responses in R/R Multiple Myeloma
Combining talquetamab with teclistamab elicits responses even among those with extramedullary disease in the RedirecTT-1 trial.
MANIFEST-2: Pelabresib in Myelofibrosis: MOA, Study Design, and Spleen Volume Reduction
Panelists discuss the MANIFEST-2 trial of pelabresib in myelofibrosis, focusing on its mechanism of action (MOA), study design, and impact on spleen volume reduction.